Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure.
OBJECTIVE
Effects of loprinone hydrochloride on plasma ET-1 and TNF-alpha levels were assessed in patients with acute heart failure (AHF).


RESULTS
Thirty patients with AHF were divided into 2 groups and treated with loprinone hydrochloride (0.3 pg/kg/min) (n = 15) or placebo (n = 15). Twenty healthy controls were also included. Plasma ET-1 and TNF-alpha were significantly higher in the 30 AHF patients than in the healthy controls. In AHF patients, loprinone hydrochloride lowered plasma ET-1 and TNF-alpha (p < 0.01).


CONCLUSIONS
ET-1 and TNF-alpha may play pathophysiological roles in the progression of AHF. Loprinone hydrochloride is effective in reducing plasma ET-1 and TNF-alpha levels in AHF patients.
Nakamura
Tsukasa
T
Department of Medicine, Misato Junshin Hospital, Saitama, Japan.
Suzuki
Shingo
S
Ushiyama
Chifuyu
C
Shimada
Noriaki
N
Koide
Hikaru
H
D000328:Adult; D002316:Cardiotonic Agents / Q000494:pharmacology*; D019332:Endothelin-1 / Q000097:blood*; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011728:Pyridones / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
D002316:Cardiotonic Agents; D019332:Endothelin-1; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D011728:Pyridones; D014409:Tumor Necrosis Factor-alpha; C059498:olprinone